Purpose: Stage I epithelial ovarian cancer (EOC) represents about 10% of all EOCs and is characterized by good prognosis with fewer than 20% of patients relapsing. As it occurs less frequently than advanced-stage EOC, its molecular features have not been thoroughly investigated. We have demonstrated that in stage I EOC miR-200c-3p can predict patients' outcome. In the present study, we analyzed the expression of long non-coding RNAs (lncRNA) to enable potential definition of a non-coding transcriptional signature with prognostic relevance for stage I EOC. Experimental Design: 202 snap-frozen stage I EOC tumor biopsies, 47 of which relapsed, were gathered together from three independent tumor tissue collections and subdivided into a training set (n = 73) and a validation set (n = 129). Median follow up was 9 years. LncRNAs' expression profiles were correlated in univariate and multivariate analysis with overall survival (OS) and progression-free survival (PFS). Results: The expression of lnc-SERTAD2-3, lnc-SOX4-1, lnc- HRCT1-1, and PVT1 was associated in univariate and multivariate analyses with relapse and poor outcome in both training and validation sets (P < 0.001). Using the expression profiles of PVT1, lnc-SERTAD2-3, and miR-200c-3p simultaneously, it was possible to stratify patients into high and low risk. The OS for high- and low-risk individuals are 36 and 123 months, respectively (OR, 15.55; 95% confidence interval, 3.81-63.36). Conclusions: We have identified a non-coding transcriptional signature predictor of survival and biomarker of relapse for stage I EOC. Clin Cancer Res; 23(9); 2356-66.
Martini, P., Paracchini, L., Caratti, G., Mello-Grand, M., Fruscio, R., Beltrame, L., et al. (2017). LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study. CLINICAL CANCER RESEARCH, 23(9), 2356-2366.
|Citazione:||Martini, P., Paracchini, L., Caratti, G., Mello-Grand, M., Fruscio, R., Beltrame, L., et al. (2017). LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study. CLINICAL CANCER RESEARCH, 23(9), 2356-2366.|
|Tipo:||Articolo in rivista - Articolo scientifico|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||No|
|Titolo:||LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study|
|Autori:||Martini, P; Paracchini, L; Caratti, G; Mello-Grand, M; Fruscio, R; Beltrame, L; Calura, E; Sales, G; Ravaggi, A; Bignotti, E; Odicino, F; Sartori, E; Perego, P; Katsaros, D; Craparotta, I; Chiorino, G; Cagnin, S; Mannarino, L; Ceppi, L; Mangioni, C; Ghimenti, C; D'Incalci, M; Marchini, S; Romualdi, C|
|Data di pubblicazione:||2017|
|Rivista:||CLINICAL CANCER RESEARCH|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1158/1078-0432.CCR-16-1402|
|Appare nelle tipologie:||01 - Articolo su rivista|